Skip to main content

lilly-nextcure-logo

Eli Lilly will use NextCure’s Functional, Integrated, NextCure Discovery in Immuno Oncology (FIND-IO™) platform to discover and develop cancer targets for new immuno-oncology therapies, the companies said, through a collaboration set to generate more than $40 million for the Beltsville, MD, cancer drug developer.

{iframe}https://www.genengnews.com/news/lilly-nextcure-launch-cancer-immunotherapy-partnership/?utm_medium=newsletter&utm_source=GEN+Daily+News+Highlights&utm_content=01&utm_campaign=GEN+Daily+News+Highlights_20181106&ajs_uid=1673D8247356B7U&oly_enc_id=1673D8247356B7U&ajs_trait_oebid=9675B9130356B7S{/iframe}

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.